Madi Madiyalakan, Ph.D
Chief Executive Officer, Director
Dr. Madiyalakan is the CEO of Quest PharmaTech since August, 2006; and Director since July, 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 25 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of a number of patents.
Lorne Meikle, B.A.
Mr. Meikle is currently the President and Chief Executive Officer of Management Dynamics Ltd., LOB Ordeins Inc., President and Chair of The Biotechnology Initiative (TBI), the former President & CEO of BCY LifeSciences Inc. (TSXV:BCY),and serves as a director on three other Boards. Mr. Meikle, was born and raised in Edmonton and is an economics graduate from the University of Manitoba. He has more than 40 years of senior management, marketing and sales management, and director experience in the health care industry. He was a member of the senior management groups at Glaxo Canada, Smith Kline and French, Ortho-McNeil and directed the International marketing program at Connaught Laboratories, now Sanofi Pasteur. In recent years he was President of TBI, before returning for a second term; Vice President, Immunovaccine Technologies Inc.; President and Chief Executive Officer of Seragen Biopharmaceuticals Ltd., the Canadian affiliate of Seragen Inc., now part of Ligand, Inc; CEO of GeneSense Technologies Inc., now part of Lorus Therapeutics; and chaired the steering committee for BIO 2002 in Toronto. Additionally, he was the President, Chief Executive Officer, Founder and a director of BioCatalyst Yorkton Inc., a venture management company that specialized in the formation of, and management of early-stage healthcare companies. Mr. Meikle resides in Toronto.
Ian McConnan, F.C.A.
Mr. McConnan is formerly a partner with Myers Norris Penny LLP, Chartered Accountants. Mr. McConnan retired in 2011. He continues to work in voluntary positions with the Canadian and Alberta Institutes of Chartered Accountants in the areas on standards and discipline. He received a B.Comm. from the University of Alberta in 1973 and has been a member of the Institute of Chartered Accountants of Alberta (“ICAA”) since 1976 and is also a Fellow of the ICAA. Mr. McConnan was a tax manager with Clarkson Gordon (now Ernst & Young) prior to becoming involved in his own firms. He was a member of Board of the Alberta Securities Commission (“ASC”) from 1991 to 2000 and Chair of the ASC Audit Committee from 1996 to 2000.
Shawn Lu, CIM, MFin
Mr. Lu is currently the chief financial officer of Hepalink USA Inc. and has served in this capacity since 2014. Prior to joining Hepalink USA, Mr. Lu was employed as the Area Manager for BMO Bank of Montreal in the central Greater Toronto area. From 2005 to 2013, Mr. Lu worked with the TD Bank as a Residential Mortgage Manager in North York, Toronto. From 2001 to 2005, Mr. Lu worked as a senior financial advisor for TD Bank in Toronto. From 1999 to 2000, Mr. Lu was employed with ShenZhen Hepalink Biopharmaceutical Co., Ltd as the CFO and VP of Corporate Finance. From 1998 to 1999, Mr. Lu was employed as the VP of Investment and Corporate Finance with ShenZhen FuTianXin Investment Co., Ltd. From 1992 to 1998, Mr. Lu worked as the General Manager, Corporate finance department, and Manager, Investment and Finance department for China Merchant Shekou Port Co. Ltd. (a ShenZhen Stock Exchange listed company). Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing. Mr. Lu has a Canadian Investment Manager (CIM, Canada) designation and also a Master of Finance Management from Queens University, School of Business, Kingston, Ontario. Mr. Lu also holds a Certified Accountant and Certified Corporate Economist designation in China and has a Master of Corporate Economics and Business Administration from ZhongNan University, Wuhan, China.
Eric Shi, Ph.D.
Dr. Shi is a biomedical scientist specializing on cancer research and translational medicine development. Dr. Shi was the Associate Professor and then full Professor of Albert Einstein College of Medicine between 1994 – 2010, during which he led twelve national research programs funded by the U.S. National Cancer Institute (NCI) and U.S. Department of Defense (DOD). In 2010, Dr. Shi returned to China and became Vice President of the Academy of Clinical Research and Translational Medicine, Jiangsu Province. Dr. Shi leads three research projects sponsored by the China National Science Foundation, and one cancer early diagnosis research project sponsored by the National Key Technology R&D Program for the 12th Five-year Plan of China. In addition, Dr. Shi is the founder of several bio-medical companies, including most recently: Dawei BioPharma in China, a medical device company specializing on the urinary tract system, and J&Q Diagnosis in China, a medical diagnosis company building a platform of metabolomics focusing on sex hormone metabolism. After graduation from Peking University School of Medicine in 1983, Dr. Shi studied at Dartmouth Medical School where he received his Ph.D. in biochemistry.
Pierre Vermette, C.A.
Chief Financial Officer
Pierre Vermette brings to Quest PharmaTech Inc. experience in the areas of securities regulation, corporate governance and financial reporting. Prior to his employment with Quest he was employed for more than 11 years with the Alberta Securities Commission as a Securities Analyst, where he worked in Continuous Disclosure and Corporate Finance. Prior to that, he was employed as a Staff Accountant with MacKay & Partners, Chartered Accountants and also with Ernst & Young LLP.